Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on Adding Zoledronic Acid to Standard Treatment for Patients with Glioblastoma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of adding zoledronic acid to the standard treatment for patients with glioblastoma, a type of brain cancer. The treatment being tested is called Zometa, which is a solution given through an intravenous infusion. The main goal of the study is to see if this additional treatment can help improve the overall survival and the time patients live without the disease getting worse.

Participants in the study will receive either the standard treatment for glioblastoma or the standard treatment plus Zometa. The study will monitor how long patients live and how long they remain free from disease progression. The study will also look at the safety and any side effects of the treatment. The trial is designed to be open-label, meaning both the doctors and the participants will know which treatment is being given.

The study will take place over several years, with regular check-ups to assess the health and progress of the participants. The trial aims to provide valuable information on whether adding zoledronic acid to the standard therapy can offer better outcomes for patients with glioblastoma. Participants will be closely monitored for any adverse effects to ensure their safety throughout the study.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants are required to provide informed consent, confirming their understanding and agreement to comply with the study requirements.

    Participants must have completed prior treatments, including surgery or biopsy and radio-chemotherapy, with a minimum 28-day gap before starting the trial.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either the standard therapy alone or the standard therapy with the addition of zoledronic acid.

    This process ensures that each participant has an equal chance of receiving either treatment option.

  3. Step 3

    Treatment administration

    Participants receiving zoledronic acid will be administered Zometa 4 mg/100 ml solution through an intravenous infusion.

    The frequency and duration of the administration will be determined by the study protocol and the participant's response to treatment.

  4. Step 4

    Monitoring and assessments

    Participants will undergo regular monitoring to assess the effectiveness and safety of the treatment.

    Assessments will include measuring overall survival and progression-free survival, as well as monitoring for any adverse effects.

  5. Step 5

    Completion of the study

    The study is estimated to conclude by January 3, 2028.

    Upon completion, participants will have a final assessment to evaluate the outcomes of the treatment received.

Who can join the trial?

18 criteria

  • Participants must be able to give signed informed consent, which means they understand and agree to follow the study's rules and requirements.
  • Participants must have adequate organ function, which includes:
    • White blood cell count (ANC) higher than 1x109/L
    • Platelet count higher than 100x109/L
    • Liver enzymes (AST and ALT) lower than 3 times the upper limit of normal (ULN)
    • Alkaline phosphatase (ALP) lower than 3 times ULN
    • Hemoglobin level higher than 80 g/L
    • Kidney function (creatinine clearance) more than 60 mL/min
    • Serum bilirubin lower than 1.5 times ULN, except for those with Gilbert syndrome, where it should be lower than 3 times ULN
    • Women of childbearing potential must agree to remain abstinent or use effective contraception during the study and for 90 days after the last dose of study medication. Effective contraception includes methods like tubal ligation, male sterilization, or copper intrauterine devices.
    • Men must agree to remain abstinent or use a condom during the study and for 90 days after the last dose of study medication. They must also refrain from donating sperm during this period.
    • Participants must be 18 years or older at the time of signing the informed consent form.
    • Participants must have a type of brain cancer called **IDH negative (wild type) glioblastoma**.
    • Participants with multiple tumor areas in different parts of the brain (multicentric) or in the same part of the brain (multifocal) are eligible.
    • Participants must have had surgery or a biopsy of the glioblastoma.
    • Participants must have completed combined radiation and chemotherapy treatment before joining the study, with at least 28 days since the last chemotherapy dose.
    • Participants must have recovered from any side effects of previous cancer treatments to a mild level, except for hair loss, mild nerve pain, joint pain, or other non-risky side effects.
    • Participants must have an **ECOG Performance Status** of 0, 1, or 2, which means they are fully active or have some limitations but can still care for themselves. A status of 3 is allowed if it is due to permanent brain damage from glioblastoma.
    • Participants must be able and willing to swallow and keep oral medication.

Who cannot join the trial?

3 criteria

  • Patients who are not diagnosed with glioblastoma, which is a type of brain cancer, cannot participate.
  • Patients who are younger than 18 years old or older than 65 years old cannot participate.
  • Patients who are part of a vulnerable population, meaning they might need special protection or care, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Zoledronic Acid is a medication used in this trial to see if it can help improve survival rates in patients with glioblastoma, a type of brain cancer. It is being added to the standard treatment to see if it can make the treatment more effective. Zoledronic acid is known for its ability to strengthen bones and is often used to treat high calcium levels in the blood or bone problems in cancer patients. In this study, researchers are exploring its potential benefits beyond bone health, specifically in treating brain cancer.

What is already known about the treatment

Zoledronic Acid – This medication is administered intravenously, meaning it is given through a vein. It is currently being studied in clinical trials to determine its effectiveness when added to standard chemotherapy for treating glioblastoma, a type of brain cancer. Zoledronic acid is primarily used to treat bone diseases, but in this trial, its potential to improve survival rates in glioblastoma patients is being evaluated. It works by inhibiting bone resorption, which is the process of breaking down bone tissue, through its action on osteoclasts, the cells responsible for this process. Zoledronic acid belongs to a class of drugs known as bisphosphonates.

Investigated diseases

Glioblastoma – Glioblastoma is a type of brain cancer that originates from glial cells, which support nerve cells in the brain. It is known for its aggressive nature and rapid growth, often infiltrating surrounding brain tissue. Symptoms can vary depending on the tumor's location but may include headaches, seizures, and changes in personality or cognitive function. As the disease progresses, it can lead to increased pressure within the skull, causing further neurological symptoms. Glioblastoma is typically characterized by its resistance to standard treatments and its tendency to recur after initial therapy.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-519446-67-00Protocol codePSKUS-GB01Estimated enrolment80 patientsSponsorPauls Stradins Clinical University Hospital

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.